Investors

Kona Medical was founded in 2009 and is backed by leading healthcare investment firms.

Domain Associates

Domain invests primarily in young life science focused businesses with outstanding growth potential. Over its 20-year history, Domain has been involved in the creation of more than 200 companies. Its latest venture capital fund is Domain Partners VIII, which is capitalized at $500 million. Domain is located in Princeton, New Jersey and in Laguna Niguel, California.

Essex Woodlands

Established in 1985, Essex Woodlands is one of the most respected and successful healthcare venture capital and growth equity firms in the world. Essex currently has $2.5 billion under management and is investing out of its eighth fund of $900 million, which closed in 2009.

Morganthaler Ventures

Morgenthaler Ventures is a premier venture capital firm, dedicated to helping entrepreneurs build valuable companies for more than 40 years. Morgenthaler has nearly $3 billion and has invested in approximately 300 companies in the information technology and life science sectors. Representative life science companies include: IPC – The Hospitalist Company, Ardian,OncoMed, Transcend, Galleon, GlobeImmune, Moximed, SetPointMedical, Promedior, Symphony Medical, Perclose, Intergrated Vascular Systems and Medaphis. Morgenthaler has offices in Palo Alto, CA, Boston, MA and Boulder, CO.www.morgenthaler.com

Biostar Ventures

BioStar Ventures is a venture capital partnership created by some of the most successful and innovative physician thought leaders coupled with decades of venture capital experience and health care executives. The group has unique proprietary deal-flow, knowledge of new devices and protocols, insight and knowledge into the FDA, clinical and bench research, and finally the acquisition needs and in house development of the major strategic acquirers. BioStar Ventures’ capital efficient model is a unique marriage of world renowned clinicians with experienced venture capitalists. This allows BioStar Ventures to capture unique deal flow and leverage decades of scientific knowledge, clinical expertise, and patient care delivery experience in early stage medical devices to BioStar’s investors and limited partners.